Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease

Outcomes of Continuation vs Discontinuation of Adalimumab Therapy During Third Trimester of Pregnancy in Inflammatory Bowel Disease

Background and Aims: Adalimumab (ADA) transport across the placenta increases with gestational age advances. We evaluated child–mother health outcomes related to the timing of the last ADA dose before delivery. Methods: Using IBM MarketScan data, we collected records for all children exposed to ADA...

Full description

Bibliographic Details
Main Authors: Brindusa Truta, Joseph K. Canner, Sandy H. Fang, Jonathan E. Efron, Bashar Safar
Format: Article
Language:English
Published: Elsevier 2022-01-01
Series:Gastro Hep Advances
Subjects:
Adalimumab
Congenital Malformation
Pregnancy
Inflammatory Bowel Disease
Online Access:http://www.sciencedirect.com/science/article/pii/S2772572322000620

Internet

http://www.sciencedirect.com/science/article/pii/S2772572322000620

Similar Items